Boston Scientific is trading at $43.13 (-4.07%) after management said an eight-day cyberattack disrupted global operations and made third-quarter and full-year 2026 guidance unlikely to be met.
- The attack disrupted manufacturing, shipping, distribution, and supplier connectivity; systems have been restored.
- Uncertainty remains over lost procedures, competitor orders, WATCHMAN weakness, and declining FARAPULSE share.
- Broader equities are lower as hotter PPI data pressures rate-cut expectations and lifts higher-rate expectations.